NewLimit has filed a notice of an exempt offering of securities to raise $72,245,500.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, NewLimit is raising $72,245,500.00 in new funding. Sources indicate that as part of senior management President, Michael Polansky played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About NewLimit
NewLimit is a biotechnology company working to radically extend human healthspan. Were developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
To learn more about NewLimit, visit http://newlimit.com/
Contact:
Michael Polansky, President
415-603-9539
https://www.linkedin.com/in/blbyers/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.